menu
    • menu
    [{"orgOrder":0,"company":"Rege Nephro","sponsor":"DCI Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Series B Financing","leadProduct":"Tamibarotene","moa":"RAR-alpha","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rege Nephro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rege Nephro \/ DCI Partners","highestDevelopmentStatusID":"8","companyTruncated":"Rege Nephro \/ DCI Partners"},{"orgOrder":0,"company":"Rege Nephro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"RAR-alpha","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rege Nephro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rege Nephro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rege Nephro \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Rege Nephro

    Menu

    Rege Nephro

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Rege Nephro

    Japan arrow
    German Wound Congress
    Not Confirmed

    Rege Nephro

    Japan arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tamibarotene

    Therapeutic Area : Genetic Disease

    Study Phase : Phase II

    Sponsor : DCI Partners

    Deal Size : $16.7 million

    Deal Type : Series B Financing

    DEALS_DEV arrow-down

    Rege Nephro Completes Series B Funding For Kidney Disease Therapy Trials

    Details : The funds will be used to advance the clinical trials of RN-014 (tamibarotene), company's retinoic acid receptor (RAR) agonist treatment, in Phase 2 for Autosomal Dominant Polycystic Kidney Disease.

    Product Name : RN-014

    Product Type : Vitamins/Minerals/Inorganic Salts

    Upfront Cash : Undisclosed

    July 10, 2024

    Lead Product(s) : Tamibarotene

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase II

    Sponsor : DCI Partners

    Deal Size : $16.7 million

    Deal Type : Series B Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Rege Nephro

    Japan arrow
    German Wound Congress
    Not Confirmed

    Rege Nephro

    Japan arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tamibarotene

    Therapeutic Area : Genetic Disease

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Rege Nephro Enrolls Patients For Phase II Tamibarotene ADPKD Trial

    Details : RN-014 (tamibarotene), under development for ADPKD, is a retinoic acid receptor (RAR) agonist expected to potently inhibit cyst formation and improve renal function.

    Product Name : RN-014

    Product Type : Vitamins/Minerals/Inorganic Salts

    Upfront Cash : Inapplicable

    May 28, 2024

    Lead Product(s) : Tamibarotene

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth